BACKGROUND: The combination of ataxia and hypogonadism was first described more than a century ago, but its genetic basis has remained elusive. METHODS: We performed whole-exome sequencing in a patient with ataxia and hypogonadotropic hypogonadism, followed by targeted sequencing of candidate genes in similarly affected patients. Neurologic and reproductive endocrine phenotypes were characterized in detail. The effects of sequence variants and the presence of an epistatic interaction were tested in a zebrafish model. RESULTS: Digenic homozygous mutations in RNF216 and OTUD4, which encode a ubiquitin E3 ligase and a deubiquitinase, respectively, were found in three affected siblings in a consanguineous family. Additional screening identified compound heterozygous truncating mutations in RNF216 in an unrelated patient and single heterozygous deleterious mutations in four other patients. Knockdown of rnf216 or otud4 in zebrafish embryos induced defects in the eye, optic tectum, and cerebellum; combinatorial suppression of both genes exacerbated these phenotypes, which were rescued by nonmutant, but not mutant, human RNF216 or OTUD4 messenger RNA. All patients had progressive ataxia and dementia. Neuronal loss was observed in cerebellar pathways and the hippocampus; surviving hippocampal neurons contained ubiquitin-immunoreactive intranuclear inclusions. Defects were detected at the hypothalamic and pituitary levels of the reproductive endocrine axis. CONCLUSIONS: The syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be caused by inactivating mutations in RNF216 or by the combination of mutations in RNF216 and OTUD4. These findings link disordered ubiquitination to neurodegeneration and reproductive dysfunction and highlight the power of whole-exome sequencing in combination with functional studies to unveil genetic interactions that cause disease. (Funded by the National Institutes of Health and others.).
BACKGROUND: The combination of ataxia and hypogonadism was first described more than a century ago, but its genetic basis has remained elusive. METHODS: We performed whole-exome sequencing in a patient with ataxia and hypogonadotropic hypogonadism, followed by targeted sequencing of candidate genes in similarly affected patients. Neurologic and reproductive endocrine phenotypes were characterized in detail. The effects of sequence variants and the presence of an epistatic interaction were tested in a zebrafish model. RESULTS: Digenic homozygous mutations in RNF216 and OTUD4, which encode a ubiquitin E3 ligase and a deubiquitinase, respectively, were found in three affected siblings in a consanguineous family. Additional screening identified compound heterozygous truncating mutations in RNF216 in an unrelated patient and single heterozygous deleterious mutations in four other patients. Knockdown of rnf216 or otud4 in zebrafish embryos induced defects in the eye, optic tectum, and cerebellum; combinatorial suppression of both genes exacerbated these phenotypes, which were rescued by nonmutant, but not mutant, humanRNF216 or OTUD4 messenger RNA. All patients had progressive ataxia and dementia. Neuronal loss was observed in cerebellar pathways and the hippocampus; surviving hippocampal neurons contained ubiquitin-immunoreactive intranuclear inclusions. Defects were detected at the hypothalamic and pituitary levels of the reproductive endocrine axis. CONCLUSIONS: The syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be caused by inactivating mutations in RNF216 or by the combination of mutations in RNF216 and OTUD4. These findings link disordered ubiquitination to neurodegeneration and reproductive dysfunction and highlight the power of whole-exome sequencing in combination with functional studies to unveil genetic interactions that cause disease. (Funded by the National Institutes of Health and others.).
Authors: Karl P Schlingmann; Martin Konrad; Nikola Jeck; Petra Waldegger; Stephan C Reinalter; Martin Holder; Hannsjörg W Seyberth; Siegfried Waldegger Journal: N Engl J Med Date: 2004-03-25 Impact factor: 91.245
Authors: G De Michele; A Filla; F P D'Armiento; S Striano; F Barbieri; G Salvatore; V Di Carlo; D Mansi Journal: Clin Neurol Neurosurg Date: 1990 Impact factor: 1.876
Authors: Jose L Badano; Carmen C Leitch; Stephen J Ansley; Helen May-Simera; Shaneka Lawson; Richard Alan Lewis; Philip L Beales; Harry C Dietz; Shannon Fisher; Nicholas Katsanis Journal: Nature Date: 2005-12-04 Impact factor: 49.962
Authors: Andrew Dauber; Christelle Golzio; Cécile Guenot; Francine M Jodelka; Maria Kibaek; Susanne Kjaergaard; Bruno Leheup; Danielle Martinet; Malgorzata J M Nowaczyk; Jill A Rosenfeld; Susan Zeesman; Janice Zunich; Jacques S Beckmann; Joel N Hirschhorn; Michelle L Hastings; Sebastien Jacquemont; Nicholas Katsanis Journal: Am J Hum Genet Date: 2013-10-17 Impact factor: 11.025
Authors: Claire Guissart; Xenia Latypova; Paul Rollier; Tahir N Khan; Hannah Stamberger; Kirsty McWalter; Megan T Cho; Susanne Kjaergaard; Sarah Weckhuysen; Gaetan Lesca; Thomas Besnard; Katrin Õunap; Lynn Schema; Andreas G Chiocchetti; Marie McDonald; Julitta de Bellescize; Marie Vincent; Hilde Van Esch; Shannon Sattler; Irman Forghani; Isabelle Thiffault; Christine M Freitag; Deborah Sara Barbouth; Maxime Cadieux-Dion; Rebecca Willaert; Maria J Guillen Sacoto; Nicole P Safina; Christèle Dubourg; Lauren Grote; Wilfrid Carré; Carol Saunders; Sander Pajusalu; Emily Farrow; Anne Boland; Danielle Hays Karlowicz; Jean-François Deleuze; Monica H Wojcik; Rena Pressman; Bertrand Isidor; Annick Vogels; Wim Van Paesschen; Lihadh Al-Gazali; Aisha Mohamed Al Shamsi; Mireille Claustres; Aurora Pujol; Stephan J Sanders; François Rivier; Nicolas Leboucq; Benjamin Cogné; Souphatta Sasorith; Damien Sanlaville; Kyle Retterer; Sylvie Odent; Nicholas Katsanis; Stéphane Bézieau; Michel Koenig; Erica E Davis; Laurent Pasquier; Sébastien Küry Journal: Am J Hum Genet Date: 2018-04-12 Impact factor: 11.025
Authors: A Deik; B Johannes; J C Rucker; E Sánchez; S E Brodie; E Deegan; K Landy; Y Kajiwara; S Scelsa; R Saunders-Pullman; C Paisán-Ruiz Journal: J Neurol Date: 2014-09-30 Impact factor: 4.849